MAPT and Alzheimer disease: Preclinical and clinical studies of dual Aβ and tau modulators have shown that a dual regulatory approach to inhibiting Aβ and tau aggregation or dissociating Aβ and tau aggregates may represent an effective strategy for the treatment of AD [37–42].